A Non-VH1-69 Heterosubtypic Neutralizing Human Monoclonal Antibody Protects Mice Against H1N1 and H5N1 Viruses

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Apr 13

PMID 22496802

Citations 24

Authors

Donata De Marco

Nicola Clementi

Nicasio Mancini

Laura Solforosi

Guisella J Moreno

Xiangjie Sun

Terrence M Tumpey

Larisa V Gubareva

Vasiliy Mishin

Massimo Clementi

Roberto Burioni

Affiliations

Soon will be listed here.

Abstract

Influenza viruses are among the most important human pathogens and are responsible for annual epidemics and sporadic, potentially devastating pandemics. The humoral immune response plays an important role in the defense against these viruses, providing protection mainly by producing antibodies directed against the hemagglutinin (HA) glycoprotein. However, their high genetic variability allows the virus to evade the host immune response and the potential protection offered by seasonal vaccines. The emergence of resistance to antiviral drugs in recent years further limits the options available for the control of influenza. The development of alternative strategies for influenza prophylaxis and therapy is therefore urgently needed. In this study, we describe a human monoclonal antibody (PN-SIA49) that recognizes a highly conserved epitope located on the stem region of the HA and able to neutralize a broad spectrum of influenza viruses belonging to different subtypes (H1, H2 and H5). Furthermore, we describe its protective activity in mice after lethal challenge with H1N1 and H5N1 viruses suggesting a potential application in the treatment of influenza virus infections.

Citing Articles

Multiplexed Antibody Sequencing and Profiling of the Human Hemagglutinin-specific Memory B Cell Response following Influenza Vaccination.

Raju N, Kramer K, Cavallaro M, Diotti R, Shiakolas A, Campos Mota Y J Immunol. 2024; 213(11):1605-1619.

PMID: 39441352 PMC: 11573632. DOI: 10.4049/jimmunol.2400326.

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses.

Voronina D, Shcheblyakov D, Esmagambetov I, Derkaev A, Popova O, Shcherbinin D Acta Naturae. 2022; 13(4):33-41.

PMID: 35127144 PMC: 8807538. DOI: 10.32607/actanaturae.11495.

Dual oxidase 1 promotes antiviral innate immunity.

Sarr D, Gingerich A, Asthiwi N, Almutairi F, Sautto G, Ecker J Proc Natl Acad Sci U S A. 2021; 118(26).

PMID: 34168077 PMC: 8256044. DOI: 10.1073/pnas.2017130118.

Influenza Virus and SARS-CoV-2 Vaccines.

Sandor A, Sturdivant M, Ting J J Immunol. 2021; 206(11):2509-2520.

PMID: 34021048 PMC: 8722349. DOI: 10.4049/jimmunol.2001287.

Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus.

Huang J, Huang N, Fan M, Zhao L, Luo Y, Ding P Virol J. 2020; 17(1):191.

PMID: 33287849 PMC: 7720065. DOI: 10.1186/s12985-020-01458-z.

References

Fiore A, Shay D, Broder K, Iskander J, Uyeki T, Mootrey G . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008; 57(RR-7):1-60. View

Friesen R, Koudstaal W, Koldijk M, Weverling G, Brakenhoff J, Lenting P . New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One. 2010; 5(2):e9106. PMC: 2817000. DOI: 10.1371/journal.pone.0009106. View

Ma J, Hunjan M, Smith R, Kelly C, Lehner T . An investigation into the mechanism of protection by local passive immunization with monoclonal antibodies against Streptococcus mutans. Infect Immun. 1990; 58(10):3407-14. PMC: 313668. DOI: 10.1128/iai.58.10.3407-3414.1990. View

Smith N, Bresee J, Shay D, Uyeki T, Cox N, Strikas R . Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-10):1-42. View

Fraser C, Donnelly C, Cauchemez S, Hanage W, Van Kerkhove M, Hollingsworth T . Pandemic potential of a strain of influenza A (H1N1): early findings. Science. 2009; 324(5934):1557-61. PMC: 3735127. DOI: 10.1126/science.1176062. View

Cheng P, Leung T, Ho E, Leung P, Ng A, Lai M . Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis. 2009; 15(6):966-8. PMC: 2727327. DOI: 10.3201/eid1506.081357. View

Ekiert D, Friesen R, Bhabha G, Kwaks T, Jongeneelen M, Yu W . A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011; 333(6044):843-50. PMC: 3210727. DOI: 10.1126/science.1204839. View

Sui J, Hwang W, Perez S, Wei G, Aird D, Chen L . Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009; 16(3):265-73. PMC: 2692245. DOI: 10.1038/nsmb.1566. View

Ramirez-Gonzalez J, Gonzalez-Duran E, Alcantara-Perez P, Wong-Arambula C, Olivera-Diaz H, Cortez-Ortiz I . Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. Emerg Infect Dis. 2011; 17(2):283-6. PMC: 3204764. DOI: 10.3201/eid1702.100897. View

10.

Trifonov V, Khiabanian H, Rabadan R . Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N Engl J Med. 2009; 361(2):115-9. DOI: 10.1056/NEJMp0904572. View

11.

Burioni R, Canducci F, Clementi M . Pregnancy and H1N1 infection. Lancet. 2009; 374(9699):1417. DOI: 10.1016/S0140-6736(09)61853-5. View

12.

Lamarre A, Talbot P . Protection from lethal coronavirus infection by immunoglobulin fragments. J Immunol. 1995; 154(8):3975-84. View

13.

Corti D, Suguitan Jr A, Pinna D, Silacci C, Fernandez-Rodriguez B, Vanzetta F . Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010; 120(5):1663-73. PMC: 2860935. DOI: 10.1172/JCI41902. View

14.

Weiss G, Watanabe C, Zhong A, Goddard A, Sidhu S . Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci U S A. 2000; 97(16):8950-4. PMC: 16802. DOI: 10.1073/pnas.160252097. View

15.

Palese P . Influenza: old and new threats. Nat Med. 2004; 10(12 Suppl):S82-7. DOI: 10.1038/nm1141. View

16.

Perotti M, Mancini N, Diotti R, Tarr A, Ball J, Owsianka A . Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol. 2007; 82(2):1047-52. PMC: 2224572. DOI: 10.1128/JVI.01986-07. View

17.

Moscona A . Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009; 360(10):953-6. DOI: 10.1056/NEJMp0900648. View

18.

Webster R . 1918 Spanish influenza: the secrets remain elusive. Proc Natl Acad Sci U S A. 1999; 96(4):1164-6. PMC: 33548. DOI: 10.1073/pnas.96.4.1164. View

19.

Clementi N, De Marco D, Mancini N, Solforosi L, Moreno G, Gubareva L . A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 2011; 6(12):e28001. PMC: 3230632. DOI: 10.1371/journal.pone.0028001. View

20.

Throsby M, van den Brink E, Jongeneelen M, Poon L, Alard P, Cornelissen L . Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008; 3(12):e3942. PMC: 2596486. DOI: 10.1371/journal.pone.0003942. View